Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Irreversible kinase inhibitors gain traction.

Sanderson K.

Nat Rev Drug Discov. 2013 Sep;12(9):649-51. doi: 10.1038/nrd4103. No abstract available.

PMID:
23989776
2.

Afatinib (Gilotrif) for advanced non-small cell lung cancer.

[No authors listed]

Med Lett Drugs Ther. 2015 May 25;57(1469):e82-3. No abstract available.

PMID:
26039556
3.

The second wave in kinase cancer drugs.

Garber K.

Nat Biotechnol. 2006 Feb;24(2):127-30. No abstract available.

PMID:
16465146
4.

Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.

Friedrich MJ.

J Natl Cancer Inst. 2009 Aug 5;101(15):1039-41. doi: 10.1093/jnci/djp243. Epub 2009 Jul 28. No abstract available.

5.

Conflicting signals on US accelerated approvals.

Fox JL.

Nat Biotechnol. 2005 Sep;23(9):1027-8. No abstract available.

PMID:
16151377
6.

From genome to drugs: where do we stand?

Schmidt C.

J Natl Cancer Inst. 2011 Jul 6;103(13):996-7. doi: 10.1093/jnci/djr252. Epub 2011 Jun 21. No abstract available.

7.

Lapatinib for advanced or metastatic breast cancer.

Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH.

Oncologist. 2012;17(4):536-42. doi: 10.1634/theoncologist.2011-0461. Epub 2012 Apr 3. Review.

8.

Drug discovery: playing dirty.

Frantz S.

Nature. 2005 Oct 13;437(7061):942-3. No abstract available.

PMID:
16222266
9.

Cancer drugs. Smart weapons prove tough to design.

Couzin J.

Science. 2002 Oct 18;298(5593):522-5. No abstract available.

PMID:
12386312
10.

Investigational drug access taken to task in lawsuit against FDA.

Randal J.

J Natl Cancer Inst. 2003 Dec 17;95(24):1818-20. No abstract available.

11.

More than just an oncogene translocation and a kinase inhibitor: Kevin's story.

Costa DB.

J Clin Oncol. 2012 Jan 1;30(1):110-2. doi: 10.1200/JCO.2011.39.4486. Epub 2011 Nov 7. No abstract available.

12.

Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma.

Leone F, Pignochino Y, Cavalloni G, Aglietta M.

J Clin Oncol. 2007 Mar 20;25(9):1145; author reply 1145-6. No abstract available.

13.

Larger companies dominate cancer companion diagnostic approvals.

Schmidt C.

Nat Biotechnol. 2011 Nov 8;29(11):955-7. doi: 10.1038/nbt1111-955. No abstract available.

PMID:
22068512
14.

Two targets, one drug for new EGFR inhibitors.

McNeil C.

J Natl Cancer Inst. 2006 Aug 16;98(16):1102-3. No abstract available. Erratum in: J Natl Cancer Inst. 2006 Oct 18;98(20):1442.

15.

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.

Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR.

Anticancer Drugs. 2009 Mar;20(3):179-84. doi: 10.1097/CAD.0b013e328325a867.

16.

A dose of reality for rational therapies.

[No authors listed]

Nat Biotechnol. 2005 Mar;23(3):267. No abstract available.

PMID:
15765066
17.

FDA announces fast track approval of new drug for lung cancer.

Dyer O.

BMJ. 2003 May 10;326(7397):1004. No abstract available.

18.

Drug developers unveil strategies aimed at imatinib-resistant CML.

Goozner M.

J Natl Cancer Inst. 2010 May 5;102(9):593-5. doi: 10.1093/jnci/djq163. Epub 2010 Apr 26. No abstract available.

19.

Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.

[No authors listed]

Prescrire Int. 2011 Oct;20(120):234. No abstract available.

PMID:
21970082
20.

Biotech industry tries to recover from 2-year lull.

Brower V.

J Natl Cancer Inst. 2003 Mar 5;95(5):348-9. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk